Increased Circulating Osteopontin Levels Promote Primary Tumour Growth, but Do Not Induce Metastasis in Melanoma
暂无分享,去创建一个
J. Sleeman | B. Garvalov | Rafael Saup | A. Schmaus | J. Shen | W. Thiele | Nidhi Nair | Jingyi Shen | Jingyi Shen
[1] W. Jiang,et al. Osteopontin and Cancer: Insights into Its Role in Drug Resistance , 2023, Biomedicines.
[2] M. Shinohara,et al. Osteopontin (OPN)/SPP1: From its biochemistry to biological functions in the innate immune system and the central nervous system (CNS). , 2022, International immunology.
[3] S. Liebner,et al. Anti-osteopontin therapy leads to improved edema and infarct size in a murine model of ischemic stroke , 2022, Scientific Reports.
[4] Y. Kariya,et al. Osteopontin in Cancer: Mechanisms and Therapeutic Targets , 2022, International Journal of Translational Medicine.
[5] Xiaoxiong Jia,et al. Profiling the neurovascular unit unveils detrimental effects of osteopontin on the blood–brain barrier in acute ischemic stroke , 2022, Acta Neuropathologica.
[6] Yaohong Wu,et al. Osteopontin in autoimmune disorders: current knowledge and future perspective , 2022, Inflammopharmacology.
[7] S. Dietmann,et al. Identification of kidney injury released circulating osteopontin as causal agent of respiratory failure , 2022, Science advances.
[8] W. Tong,et al. Macrophages in epididymal adipose tissue secrete osteopontin to regulate bone homeostasis , 2022, Nature communications.
[9] G. Cappellano,et al. High levels of circulating osteopontin in inflammatory lung disease regardless of SARS‐CoV‐2 infection , 2021, EMBO molecular medicine.
[10] M. Rothley,et al. Quantitative Detection of Disseminated Melanoma Cells by Trp-1 Transcript Analysis Reveals Stochastic Distribution of Pulmonary Metastases , 2021, Journal of clinical medicine.
[11] J. Utikal,et al. IER2-induced senescence drives melanoma invasion through osteopontin , 2021, Oncogene.
[12] G. Long,et al. Immune checkpoint inhibitors in melanoma , 2021, The Lancet.
[13] Yukio Fujiwara,et al. Soluble Factors Involved in Cancer Cell–Macrophage Interaction Promote Breast Cancer Growth , 2021, AntiCancer Research.
[14] A. Mirzaei,et al. Evaluation of local and circulating osteopontin in malignant and benign primary bone tumors , 2021, Journal of bone oncology.
[15] Changzheng Huang,et al. The role of osteopontin in the development and metastasis of melanoma , 2021, Melanoma research.
[16] Dafeng Yang,et al. Osteopontin Blockade Immunotherapy Increases Cytotoxic T Lymphocyte Lytic Activity and Suppresses Colon Tumor Progression , 2021, Cancers.
[17] Kebin Liu,et al. Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation , 2020, Cancers.
[18] G. Cappellano,et al. Osteopontin binds ICOSL promoting tumor metastasis , 2020, Communications biology.
[19] Juan Su,et al. BET inhibitor suppresses melanoma progression via the noncanonical NF-κB/SPP1 pathway , 2020, Theranostics.
[20] Deepali V. Sawant,et al. Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer , 2020, Cell.
[21] Chaowei Wang,et al. Osteopontin in Bone Metabolism and Bone Diseases , 2020, Medical science monitor : international medical journal of experimental and clinical research.
[22] R. Matusik,et al. Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia , 2019, bioRxiv.
[23] Jun Li,et al. Symbiotic Macrophage-Glioma Cell Interactions Reveal Synthetic Lethality in PTEN-Null Glioma. , 2019, Cancer cell.
[24] Z. Lok,et al. Osteopontin in Vascular Disease: Friend or Foe? , 2019, Arteriosclerosis, thrombosis, and vascular biology.
[25] G. Gao,et al. Adeno-associated virus vector as a platform for gene therapy delivery , 2019, Nature Reviews Drug Discovery.
[26] K. Ozato,et al. An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion , 2018, The Journal of clinical investigation.
[27] Carola Berking,et al. Melanoma , 2018, The Lancet.
[28] M. Gezmen-Karadag,et al. The multiple functions and mechanisms of osteopontin. , 2018, Clinical biochemistry.
[29] Hailin Zhao,et al. The role of osteopontin in the progression of solid organ tumour , 2018, Cell Death & Disease.
[30] M. Perelman,et al. Metastatic cardiac tumors: from clinical presentation through diagnosis to treatment , 2018, BMC Cancer.
[31] W. Syn,et al. Osteopontin splice variants and polymorphisms in cancer progression and prognosis. , 2017, Biochimica et biophysica acta. Reviews on cancer.
[32] A. Chiocchetti,et al. Osteopontin at the Crossroads of Inflammation and Tumor Progression , 2017, Mediators of inflammation.
[33] W. Jiang,et al. Human osteopontin: Potential clinical applications in cancer (Review) , 2017, International journal of molecular medicine.
[34] I. Giopanou,et al. Tumor-derived osteopontin isoforms cooperate with TRP53 and CCL2 to promote lung metastasis , 2017, Oncoimmunology.
[35] R. Chen,et al. Osteopontin facilitates tumor metastasis by regulating epithelial–mesenchymal plasticity , 2016, Cell Death and Disease.
[36] M. Colombo,et al. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers , 2015, Oncotarget.
[37] R. Ádány,et al. The role of osteopontin expression in melanoma progression , 2015, Tumor Biology.
[38] S. Aamdal,et al. Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial , 2015, Cancer Immunology, Immunotherapy.
[39] T. Geiger,et al. Tumor-derived osteopontin reprograms normal mammary fibroblasts to promote inflammation and tumor growth in breast cancer. , 2015, Cancer research.
[40] T. Padera,et al. The lymph node microenvironment and its role in the progression of metastatic cancer. , 2015, Seminars in cell & developmental biology.
[41] Yeonseok Chung,et al. Tumor-derived osteopontin suppresses antitumor immunity by promoting extramedullary myelopoiesis. , 2014, Cancer research.
[42] Xiao-Fei Liu,et al. Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis. , 2014, Clinica chimica acta; international journal of clinical chemistry.
[43] D. Bruemmer,et al. Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes , 2014, Molecular metabolism.
[44] G. Kundu,et al. Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via α9β1 integrin , 2014, Oncogene.
[45] D. Bishop,et al. Plasma osteopontin concentrations in patients with cutaneous melanoma , 2013, Oncology reports.
[46] Dhiraj Kumar,et al. Functional Characterization of Stromal Osteopontin in Melanoma Progression and Metastasis , 2013, PloS one.
[47] C. Berking,et al. Osteopontin expression in plasma of melanoma patients and in melanocytic tumours , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.
[48] Johannes E. Schindelin,et al. Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.
[49] E. Kraynov,et al. Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer , 2012, Journal of experimental & clinical cancer research : CR.
[50] K. Alitalo,et al. Induced Pluripotent Stem Cell Clones Reprogrammed via Recombinant Adeno-Associated Virus-Mediated Transduction Contain Integrated Vector Sequences , 2012, Journal of Virology.
[51] Guoxin Zhang,et al. Osteopontin Enhances the Expression and Activity of MMP-2 via the SDF-1/CXCR4 Axis in Hepatocellular Carcinoma Cell Lines , 2011, PloS one.
[52] E. Kizana,et al. SUMO1-dependent modulation of SERCA2a in heart failure , 2011, Nature.
[53] A. Chambers,et al. Pre- and post-translational regulation of osteopontin in cancer , 2011, Journal of Cell Communication and Signaling.
[54] M. Shinohara,et al. Intracellular osteopontin (iOPN) and immunity , 2011, Immunologic research.
[55] C. Comi,et al. The role of osteopontin in neurodegenerative diseases. , 2011, Journal of Alzheimer's disease : JAD.
[56] Harish Srinivasan,et al. Identification of Potential Serum Biomarkers of Glioblastoma: Serum Osteopontin Levels Correlate with Poor Prognosis , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[57] E. Elias,et al. Cytokines and Growth Factors Expressed by Human Cutaneous Melanoma , 2010, Cancers.
[58] Hao Wang,et al. A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo , 2010, Cancer Immunology, Immunotherapy.
[59] Jingwu Z. Zhang,et al. Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis. , 2009, Arthritis and rheumatism.
[60] S. Stewart,et al. Senescent stromal-derived osteopontin promotes preneoplastic cell growth. , 2009, Cancer research.
[61] C. Betsholtz,et al. Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. , 2009, Cancer research.
[62] R. Weinberg,et al. Systemic Endocrine Instigation of Indolent Tumor Growth Requires Osteopontin , 2008, Cell.
[63] J. Rabinowitz,et al. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[64] M. Shinohara,et al. Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells , 2008, Proceedings of the National Academy of Sciences.
[65] M. Nosrati,et al. Osteopontin as a molecular prognostic marker for melanoma , 2008, Cancer.
[66] E. Ukkonen,et al. Systematic search for the best gene expression markers for melanoma micrometastasis detection , 2007, The Journal of pathology.
[67] M. Noda,et al. Serum osteopontin, an enhancer of tumor metastasis to bone, promotes B16 melanoma cell migration , 2007, Journal of cellular biochemistry.
[68] Gregory E. J. Harding,et al. Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1. , 2007, American journal of physiology. Cell physiology.
[69] M. Kaplan,et al. Plasma osteopontin is an independent prognostic marker for head and neck cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] M. Ringnér,et al. Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. , 2006, Carcinogenesis.
[71] Q. Ye,et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma , 2006, Journal of Cancer Research and Clinical Oncology.
[72] V. Bramwell,et al. Serial Plasma Osteopontin Levels Have Prognostic Value in Metastatic Breast Cancer , 2006, Clinical Cancer Research.
[73] D. Denhardt. Osteopontin expression correlates with melanoma invasion. , 2005, The Journal of investigative dermatology.
[74] Quynh-Thu Le,et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[75] H. Cantor,et al. Phosphorylation‐dependent interaction of osteopontin with its receptors regulates macrophage migration and activation , 2002, Journal of leukocyte biology.
[76] M. Noda,et al. Osteopontin Deficiency Reduces Experimental Tumor Cell Metastasis to Bone and Soft Tissues , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[77] J. Sleeman,et al. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. , 1999, Cancer research.
[78] F. O'Malley,et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[79] M. Glimcher,et al. Receptor-Ligand Interaction Between CD44 and Osteopontin (Eta-1) , 1996, Science.
[80] M C Farach-Carson,et al. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. , 1993, The Journal of biological chemistry.
[81] R. Hynes,et al. Transformed mammalian cells secrete specific proteins and phosphoproteins , 1979, Cell.